{"id":13505,"date":"2024-11-25T14:52:04","date_gmt":"2024-11-25T07:52:04","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=13505"},"modified":"2024-11-25T14:52:04","modified_gmt":"2024-11-25T07:52:04","slug":"j-ints-bio-and-md-anderson-collaborate-on-the-development-of-brain-tumor-treatment-jin-001-enhancing-radiation-and-chemotherapy-efficacy","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=13505","title":{"rendered":"J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment ‘JIN-001’ – Enhancing Radiation and Chemotherapy Efficacy"},"content":{"rendered":"

SEOUL, South Korea<\/span><\/span>, Nov. 25, 2024<\/span><\/span> \/PRNewswire\/ — J INTS BIO<\/span> announced research findings on its innovative brain tumor treatment, ‘JIN-001,’ developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA<\/span>. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy.<\/p>\n

\n

\"\" <\/a>
<\/span><\/p>\n<\/div>\n

JIN-001: Aiming to Revolutionize Brain Tumor Treatment<\/b><\/p>\n

‘JIN-001’ targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy. As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain. While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery. JIN-001 overcomes this limitation, directly attacking brain tumors and addressing the low permeability issue of existing drugs.<\/p>\n

The study also highlighted that JIN-001 demonstrated promising results when combined with standard therapies such as Radiation Therapy and Temozolomide, effectively suppressing tumor cell growth and inducing apoptosis (programmed cell death).<\/p>\n

JIN-001: Pioneering Future Clinical Developments<\/b><\/p>\n

Based on these promising findings, J INTS BIO plans to accelerate preclinical trials for JIN-001. The company intends to incorporate CRISPR gene-editing technology to identify the functional roles of specific genetic factors in treatment resistance, paving the way for precision medicine strategies. CRISPR-based techniques allow targeted modulation of gene expression, helping to predict and better understand tumor responses.<\/p>\n

J INTS BIO<\/span> is also advancing plans to commercialize JIN-001 through partnerships with global pharmaceutical companies, aiming to bring faster and more effective treatments to brain tumor patients. Furthermore, the potential applications of JIN-001 are being explored in treating a wide range of cancers beyond brain tumors, providing new hope for cancer patients worldwide.<\/p>\n

JIN-001 represents a groundbreaking innovation that transcends the limitations of existing therapies, offering new treatment opportunities and hope for improved survival and quality of life for brain tumor patients.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SEOUL, South Korea<\/span><\/span>, Nov. 25, 2024<\/span><\/span> \/PRNewswire\/ — J INTS BIO<\/span> announced research findings on its innovative brain tumor treatment, ‘JIN-001,’ developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA<\/span>. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy.<\/p>\n

\n

\"\" <\/a>
<\/span><\/p>\n<\/div>\n

JIN-001: Aiming to Revolutionize Brain Tumor Treatment<\/b><\/p>\n

‘JIN-001’ targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy. As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain. While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery. JIN-001 overcomes this limitation, directly attacking brain tumors and addressing the low permeability issue of existing drugs.<\/p>\n

The study also highlighted that JIN-001 demonstrated promising results when combined with standard therapies such as Radiation Therapy and Temozolomide, effectively suppressing tumor cell growth and inducing apoptosis (programmed cell death).<\/p>\n

JIN-001: Pioneering Future Clinical Developments<\/b><\/p>\n

Based on these promising findings, J INTS BIO plans to accelerate preclinical trials for JIN-001. The company intends to incorporate CRISPR gene-editing technology to identify the functional roles of specific genetic factors in treatment resistance, paving the way for precision medicine strategies. CRISPR-based techniques allow targeted modulation of gene expression, helping to predict and better understand tumor responses.<\/p>\n

J INTS BIO<\/span> is also advancing plans to commercialize JIN-001 through partnerships with global pharmaceutical companies, aiming to bring faster and more effective treatments to brain tumor patients. Furthermore, the potential applications of JIN-001 are being explored in treating a wide range of cancers beyond brain tumors, providing new hope for cancer patients worldwide.<\/p>\n

JIN-001 represents a groundbreaking innovation that transcends the limitations of existing therapies, offering new treatment opportunities and hope for improved survival and quality of life for brain tumor patients.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-13505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13505"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13505\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}